Overview
Cellbricks develops 3D tissue implants and organ-replacement technologies aimed at advancing regenerative medicine. Their products are intended for patients requiring organ replacement, surgical centers, and healthcare providers seeking alternatives to donor transplants. The company focuses on implantable tissue constructs designed to restore function and address organ failure. In March 2026 Silicon Roundabout backed an undisclosed financing reported as €10M (listed as $10M), representing the company's only disclosed round and bringing total raised to $10M. Cellbricks differentiates itself by concentrating on 3D tissue implants and organ-replacement solutions within the bioengineering and medical-device space.
Funding History
Silicon Roundabout backs Cellbricks’ €10M round to advance 3D tissue implants and organ replacement
Frequently Asked Questions
- How much has Cellbricks raised in total?
- Cellbricks has raised a total of $10M across 1 funding round.
- Who are Cellbricks's investors?
- Cellbricks's investors include Undisclosed.
- What does Cellbricks do?
- Cellbricks develops 3D tissue implants and organ-replacement technologies aimed at advancing regenerative medicine. Their products are intended for patients requiring organ replacement, surgical centers, and healthcare providers seeking alternatives to donor transplants. The company focuses on implantable tissue constructs designed to restore function and address organ failure. In March 2026 Silicon Roundabout backed an undisclosed financing reported as €10M (listed as $10M), representing the company's only disclosed round and bringing total raised to $10M. Cellbricks differentiates itself by concentrating on 3D tissue implants and organ-replacement solutions within the bioengineering and medical-device space.
- Where is Cellbricks headquartered?
- Cellbricks is headquartered in San Francisco, CA.
Investors
Related Insights
The definitive guide to AI startup funding in 2026 — from pre-seed through IPO, covering valuation mechanics, timelines, investor expectations, and how AI companies differ from traditional tech startups.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.